Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors

1 C. Lin, R. Clark, P. Tu, H. B. Bosworth and L. L. Zullig, Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers, Breast Cancer Res. Treat. 165(2) (2017) 247–260; https://doi.org/10.1007/s10549-017-4317-2 Search in Google Scholar

2 V. J. O’neill and C. J. Twelves, Oral cancer treatment: developments in chemotherapy and beyond, Br. J. Cancer 87(9) (2002) 933–937; https://doi.org/10.1038/sj.bjc.6600591 Search in Google Scholar

3 V. Gebbia, G. Bellavia, F. Ferra and M. R. Valerio, Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents, Expert Opin. Drug Saf. 11(1) (2012) 49–59; https://doi.org/10.1517/14740338.2011.645803 Search in Google Scholar

4 B. A. Given, S. L. Spoelstra and M. Grant, The challenges of oral agents as antineoplastic treatments, Semin. Oncol. Nurs. 27(2) (2011) 93–103; https://doi.org/10.1016/j.soncn.2011.02.003 Search in Google Scholar

5 R. Lasala and F. Santoleri, Association between adherence to oral therapies in cancer patients and clinical outcome: a systematic review of the literature, Br. J. Clin. Pharmacol. 88(5) (2022) 1999–2018; https://doi.org/10.1111/bcp.15147 Search in Google Scholar

6 L. A. Decosterd, N. Widmer, K. Zaman, E. Cardoso, T. Buclin and C. Csajka, Therapeutic drug monitoring of targeted anticancer therapy, Biomark Med. 9(9) (2015) 887–893; https://doi.org/10.2217/bmm.15.78 Search in Google Scholar

7 T. M. Atkinson, V. M. Rodríguez, M. Gordon, I. K. Avildsen, J. C. Emanu, S. T. Jewell, K. A. Anselmi and P. K. Ginex, The association between patient-reported and objective oral anticancer medication adherence measures: a systematic review, Oncol. Nurs. Forum. 43(5) (2016) 576–582; https://doi.org/10.1188/16.ONF.576-582 Search in Google Scholar

8 K. Ruddy, E. Mayer and A. Partridge, Patient adherence and persistence with oral anticancer treatment, CA Cancer J. Clin. 59(1) (2009) 56–66; https://doi.org/10.3322/caac.20004 Search in Google Scholar

9 A. Vyas, A. Descoteaux, S. Kogut, M. A. Parikh, P. J. Campbell, A. Green and K. Westrich, Predictors of adherence to oral anticancer medications: an analysis of 2010-2018 US nationwide claims, J. Manag. Care Spec. Pharm. 28(8) (2022) 831–844; https://doi.org/10.18553/jmcp.2022.28.8.831 Search in Google Scholar

10 A. M. Levine, J. L. Richardson, G. Marks, K. Chan, J. Graham, J. N. Selser, C. Kishbaugh, D. R. Shelton and C. A. Johnson, Compliance with oral drug therapy in patients with hematologic malignancy, J. Clin. Oncol. 5(9) (1987) 1469–1476; https://doi.org/10.1200/JCO.1987.5.9.1469 Search in Google Scholar

11 C. R. Lee, P. W. Nicholson, R. L. Souhami and A. A. Deshmukh, Patient compliance with oral chemo-therapy as assessed by a novel electronic technique, J. Clin. Oncol. 10(6) (1992) 1007–1013; https://doi.org/10.1200/JCO.1992.10.6.1007 Search in Google Scholar

12 L. Atkins and L. Fallowfield, Intentional and non-intentional non-adherence to medication amongst breast cancer patients, Eur. J. Cancer 42(14) (2006) 2271–2276; https://doi.org/10.1016/j.ejca.2006.03.004 Search in Google Scholar

13 J. Ferlay, M. Colombet, I. Soerjomataram, C. Mathers, D. M. Parkin, M. Piñeros, A. Znaor and F. Bray, Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods, Int. J. Cancer. 144(8) (2019) 1941–1953; https://doi.org/10.1002/ijc.31937 Search in Google Scholar

14 M. C. Kirk and C. A. Hudis, Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer, Clin. Breast Cancer 8(2) (2008) 155–161; https://doi.org/10.3816/CBC.2008.n.016 Search in Google Scholar

15 A. H. Partridge, P. S. Wang, E. P. Winer and J. Avorn, Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer, J. Clin. Oncol. 21(4) (2003) 602–606; https://doi.org/10.1200/JCO.2003.07.071 Search in Google Scholar

16 T. L. Lash, M. P. Fox, J. L. Westrup, A. K. Fink and R. A. Silliman, Adherence to tamoxifen over the five-year course, Breast Cancer Res. Treat. 99(2) (2006) 215–220; https://doi.org/10.1007/s10549-006-9193-0 Search in Google Scholar

17 A. K. Fink, J. Gurwitz, W. Rakowski, E. Guadagnoli and R. A. Silliman, Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer, J. Clin. Oncol. 22(16) (2004) 3309–3315; https://doi.org/10.1200/JCO.2004.11.064 Search in Google Scholar

18 T. I. Barron, R. M. Connolly, K. Bennett, J. Feely and M. J. Kennedy, Early discontinuation of tamoxifen: a lesson for oncologists, Cancer 109(5) (2007) 832–839; https://doi.org/10.1002/cncr.22485 Search in Google Scholar

19 M. Giuliano, F. Schettini, C. Rognoni, M. Milani, G. Jerusalem, T. Bachelot, M. De Laurentiis, G. Thomas, P. De Placido, G. Arpino, S. De Placido, M. Cristofanilli, A. Giordano, F. Puglisi, B. Pistilli, A. Prat, L. Del Mastro, S. Venturini and D. Generali, Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis, Lancet Oncol. 20(10) (2019) 1360–1369; https://doi.org/10.1016/S1470-2045(19)30420-6 Search in Google Scholar

20 R. Addeo, P. Iodice, L. Maiorino, A. Febbraro, P. Incoronato, A. Pisano, M. Bianco, R. Mabilia, F. Riccardi and S. Del Prete, Acceptance and adherence of oral endocrine therapy in women with metastatic breast cancer: exacampania group study, Breast J. 21(3) (2015) 326–328; https://doi.org/10.1111/tbj.12409 Search in Google Scholar

21 C. McCowan, J. Shearer, P. T. Donnan, J. A. Dewar, M. Crilly, A. M. Thompson and T. P. Fahey, Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer, Br. J. Cancer 99(11) (2008) 1763–1768; https://doi.org/10.1038/sj.bjc.6604758 Search in Google Scholar

22 C. Owusu, D. S. M. Buist, T. S. Field, T. L. Lash, S. S. Thwin, A. M. Geiger, V. P. Quinn, F. Frost, M. Prout, M. U. Yood, F. Wei and R. A. Silliman, Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer, J. Clin. Oncol. 26(4) (2008) 549–555; https://doi.org/10.1200/JCO.2006.10.1022 Search in Google Scholar

23 R. L. Sedjo and S. Devine, Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer, Breast Cancer Res. Treat. 125(1) (2011) 191–200; https://doi.org/10.1007/s10549-010-0952-6 Search in Google Scholar

24 R. Simon, J. Latreille, C. Matte, P. Desjardins and E. Bergeron, Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up, Can. J. Surg. 57(1) (2014) 26–32; https://doi.org/10.1503/cjs.006211 Search in Google Scholar

25 V. Wong, R. de Boer, S. Baron-Hay, R. Blum, F. Boyle, S. Chua, K. Clarke, K. Cuff, M. Green, E. Lim, K. Mok, L. Nott, M. Nottage, A. Tafreshi, D. Tsoi, A. Uccellini, W. Hong, P. Gibbs and S.W. Lok, Real-world outcomes of ribociclib and aromatase inhibitor use in first line hormone receptor positive, HER2-negative metastatic breast cancer, Clin. Breast Cancer 22(8) (2022) 792–800; https://doi.org/10.1016/j.clbc.2022.08.011 Search in Google Scholar

26 M. Piezzo, P. Chiodini, M. Riemma, S. Cocco, R. Caputo, D. Cianniello, G. Di Gioia, V. Di Lauro, F. Di Rella, G. Fusco, G. Iodice, F. Nuzzo, C. Pacilio, M. Pensabene and M. De Laurentiis, Progression-free survival and overall survival of CDK 4/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis, Int. J. Mol. Sci. 21(17) (2020) Article ID 6400 (17 pages); https://doi.org/10.3390/ijms21176400 Search in Google Scholar

27 C. Bandiera, I. Locatelli, P. Courlet, E. Cardoso, K. Zaman, A. Stravodimou, A. Dolcan, A. Sarivalasis, J. P. Zurcher, V. Aedo-Lopez, J. Dotta-Celio, S. Peters, M. Guidi, A. D. Wagner, C. Csajka and M. P. Schneider, Adherence to the CDK 4/6 inhibitor palbociclib and omission of dose management supported by pharmacometric modelling as part of the OpTAT study, Cancers (Basel) 15(1) (2023) Article ID 316 (19 pages); https://doi.org/10.3390/cancers15010316 Search in Google Scholar

28 C. C. Conley, M. K. McIntyre, N. A. Pensak, F. Lynce, D. Graham, R. Ismail-Khan, K. Lopez, S. T. Vadaparampil and S. C. O’Neill, Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study, Breast Cancer Res. Treat. 192(2) (2022) 385–399; https://doi.org/10.1007/s10549-022-06518-2 Search in Google Scholar

29 L. Turković, L. Bočkor, O. Ekpenyong, T. Silovski, M. Lovrić, S. Crnković, B. Nigović and M. Sertić, Development and validation of a novel LC-MS/MS method for the simultaneous determination of abemaciclib, palbociclib, ribociclib, anastrozole, letrozole, and fulvestrant in plasma samples: a pre-requisite for personalized breast cancer treatment, Pharmaceuticals 15(5) (2022) Article ID 614 (19 pages); https://doi.org/10.3390/ph15050614 Search in Google Scholar

30 A. H. Y. Chan, R. Horne, M. Hankins and C. Chisari, The medication adherence report scale: a measurement tool for eliciting patients’ reports of nonadherence, Br. J. Clin. Pharmacol. 86(7) (2020) 1281–1288; https://doi.org/10.1111/bcp.14193 Search in Google Scholar

31 R. Horne, K. Faasse, V. Cooper, M. A. Diefenbach, H. Leventhal, E. Leventhal and K. J. Petrie, The perceived sensitivity to medicines (PSM) scale: an evaluation of validity and reliability, Br. J. Health Psychol. 18(1) (2013) 18–30; https://doi.org/10.1111/j.2044-8287.2012.02071.x Search in Google Scholar

32 R. Horne, J. Weinman and M. Hankins, The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication, Psychol. Health 14(1) (1999) 1–24; https://doi.org/10.1080/08870449908407311 Search in Google Scholar

33 R. Horne and J. Weinman, Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness, J. Psychosom. Res. 47(6) (1999) 555–567; https://doi.org/10.1016/S0022-3999(99)00057-4 Search in Google Scholar

34 D. Wild, A. Grove, M. Martin, S. Eremenco, S. McElroy, A. Verjee-Lorenz and P. Erikson, Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation, Value Health 8(2) (2005) 94–104; https://doi.org/10.1111/j.1524-4733.2005.04054.x Search in Google Scholar

35 A. T. Beck, R. Steer, J. Brown, Manual for the Beck Depression Inventory-II; Psychological Corporation, San Antonio 1996. Search in Google Scholar

36 C. Louwrens Braal, E. M. Jongbloed, S. M. Wilting, R. H. J. Mathijssen, S. L. W. Koolen and A. Jager, Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences, Drugs 81(3) (2021) 317–331; https://doi.org/10.1007/s40265-020-01461-2 Search in Google Scholar

37 K. Tamura, H. Mukai, Y. Naito, K. Yonemori, M. Kodaira, Y. Tanabe, N. Yamamoto, S. Osera, M. Sasaki, Y. Mori, S. Hashigaki, T. Nagasawa, Y. Umeyama and T. Yoshino, Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients, Cancer Sci. 107(6) (2016) 755–763; https://doi.org/10.1111/cas.12932 Search in Google Scholar

38 T. S. Samant, S. Dhuria, Y. Lu, M. Laisney, S. Yang, A. Grandeury, M. Mueller-Zsigmondy, K. Umehara, F. Huth, M. Miller, C. Germa and M. Elmeliegy, Ribociclib bioavailability is not affected by gastric pH changes or food intake: in silico and clinical evaluations, Clin. Pharmacol. Ther. 104(2) (2018) 374–383; https://doi.org/10.1002/cpt.940 Search in Google Scholar

39 A. Le Marouille, E. Petit, C. Kaderbhaï, I. Desmoulins, A. Hennequin, D. Mayeur, J. D. Fumet, S. Ladoire, Z. Tharin, S. Ayati, S. Ilie, B. Royer and A. Schmitt, Pharmacokinetic/pharmacodynamic model of neutropenia in real-life palbociclib-treated patients, Pharmaceutics 13(10) (2021) Article ID 1708 (14 pages); https://doi.org/10.3390/pharmaceutics13101708 Search in Google Scholar

40 P. Courlet, E. Cardoso, C. Bandiera, A. Stravodimou, J. P. Zurcher, H. Chtioui, I. Locatelli, L. A. Decosterd, L. Darnaud, B. Blanchet, J. Alexandre, A. D. Wagner, K. Zaman, M. P. Schneider, M. Guidi and C. Csajka, Population pharmacokinetics of palbociclib and its correlation with clinical efficacy and safety in patients with advanced breast cancer, Pharmaceutics 14(7) (2022) Article ID 1317 (17 pages); https://doi.org/10.3390/pharmaceutics14071317 Search in Google Scholar

41 P. Kardas, P. Lewek and M. Matyjaszczyk, Determinants of patient adherence: a review of systematic reviews, Front. Pharmacol. 4 (2013) Article ID 91 (16 pages); https://doi.org/10.3389/fphar.2013.00091 Search in Google Scholar

42 G. Kimmick, S. N. Edmond, H. B. Bosworth, J. Peppercorn, P. K. Marcom, K. Blackwell, F. J. Keefe and R. A. Shelby, Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy, Breast 24(5) (2015) 630–636; https://doi.org/10.1016/j.breast.2015.06.010 Search in Google Scholar

43 H. Wouters, A. M. Stiggelbout, M. L. Bouvy, G. A. Maatman, E. C. G. Van Geffen, R. Vree, J. W. Nortier and L. Van Dijk, Endocrine therapy for breast cancer: assessing an array of women’s treatment experiences and perceptions, their perceived self-efficacy and nonadherence, Clin. Breast Cancer 14(6) (2014) 460–467; https://doi.org/10.1016/j.clbc.2014.04.005 Search in Google Scholar

44 C. Bolman, T. G. Arwert and T. Völlink, Adherence to prophylactic asthma medication: habit strength and cognitions, Heart Lung 40(1) (2011) 63–75; https://doi.org/10.1016/j.hrtlng.2010.02.003 Search in Google Scholar

45 L. Alison Phillips, H. Leventhal and E. A. Leventhal, Assessing theoretical predictors of long-term medication adherence: patients’ treatment-related beliefs, experiential feedback and habit development, Psychol. Health 28(10) (2013) 1135–1151; https://doi.org/10.1080/08870446.2013.793798 Search in Google Scholar

46 A. S. Gadkari and C. A. Mchorney, Unintentional non-adherence to chronic prescription medications: how unintentional is it really?, BMC Health Serv. Res. 12 (2012) Article ID 98 (12 pages); https://doi.org/10.1186/1472-6963-12-98 Search in Google Scholar

47 M. Meegdes, S. M. E. Geurts, F. L. G. Erdkamp, M. W. Dercksen, B. E. P. J. Vriens, K. N. A. Aaldering, M. J. A. E. Pepels, L. M. H. van de Winkel, N. J. A. Teeuwen, M. de Boer and V. C. G. Tjan-Heijnen, The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2-advanced breast cancer patients: a study of the Dutch SONABRE Registry, Int. J. Cancer 150(1) (2022) 124–131; https://doi.org/10.1002/ijc.33785 Search in Google Scholar

48 F. Després, A. Forget, F.-Z. Kettani and L. Blais, Impact of patient reimbursement timing and patient out-of-pocket expenses on medication adherence in patients covered by private drug insurance plans, J. Manag. Care Spec. Pharm. 22(5) (2016) 539–547; https://doi.org/10.18553/jmcp.2016.22.5.539 Search in Google Scholar

49 S. Schneeweiss, A. R. Patrick, M. Maclure, C. R. Dormuth and R. J. Glynn, Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment, Circulation 115(16) (2007) 2128–2135; https://doi.org/10.1161/CIRCULATIONAHA.106.665992 Search in Google Scholar

50 M. E. Patterson, S. J. Blalock, A. J. Smith and M. D. Murray, Associations between prescription copayment levels and β-blocker medication adherence in commercially insured heart failure patients 50 years and older, Clin. Ther. 33(5) (2011) 608–616; https://doi.org/10.1016/j.clinthera.2011.04.022 Search in Google Scholar

51 S. Gupta, M. A. McColl, S. J. Guilcher and K. Smith, Cost-related nonadherence to prescription medications in Canada: a scoping review, Patient Prefer. Adherence 12 (2018) 1699–1715; https://doi.org/10.2147/PPA.S170417 Search in Google Scholar

52 L. Husinka, P. H. Koerner, R. T. Miller and W. Trombatt, Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer, J. Drug Assess. 10(1) (2021) 27–34; https://doi.org/10.1080/21556660.2020.1857103 Search in Google Scholar

53 A. Marra and G. Curigliano, Are all cyclin-dependent kinases 4/6 inhibitors created equal?, NPJ Breast Cancer 5 (2019) Article ID 27 (9 pages); https://doi.org/10.1038/s41523-019-0121-y Search in Google Scholar

54 J. L. Grenard, B. A. Munjas, J. L. Adams, M. Suttorp, M. Maglione, E. A. McGlynn and W. F. Gellad, Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis, J. Gen. Intern. Med. 26(10) (2011) 1175–1182; https://doi.org/10.1007/s11606-011-1704-y Search in Google Scholar

55 B. T. Mausbach, R. B. Schwab and S. A. Irwin, Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis, Breast Cancer Res. Treat. 152(2) (2015) 239–246; https://doi.org/10.1007/s10549-015-3471-7 Search in Google Scholar

56 C. Burgess, V. Cornelius, S. Love, J. Graham, M. Richards and A. Ramirez, Depression and anxiety in women with early breast cancer: five year observational cohort study, Br. Med. J. 330(7493) (2005) 702–705; https://doi.org/10.1136/bmj.38343.670868.D3 Search in Google Scholar

57 K. M. Christie, B. E. Meyerowitz and R. C. Maly, Depression and sexual adjustment following breast cancer in low-income Hispanic and non-Hispanic white women, Psychooncology 19(10) (2010) 1069–1077; https://doi.org/10.1002/pon.1661 Search in Google Scholar

58 F. Trinca, P. Infante, R. Dinis, M. Inácio, E. Bravo, J. Caravana, T. Reis and S. Marques, Depression and quality of life in patients with breast cancer undergoing chemotherapy and monoclonal antibodies, Ecancermedicalscience 13 (2019) Article ID 937 (20 pages); https://doi.org/10.3332/ecancer.2019.937 Search in Google Scholar

59 M. Thakur, R. Sharma, A. K. Mishra and K. R. Singh, Prevalence and psychobiological correlates of depression among breast cancer patients, Indian J. Surg. Oncol. 12(2) (2021) 251–257; https://doi.org/10.1007/s13193-021-01296-7 Search in Google Scholar

60 C. Brito, C. Portela, M. Teixeira and L. De Vasconcellos, Adherence to hormone therapy among women with breast cancer, BMC Cancer 14 (2014) Article ID 397 (8 pages); https://doi.org/10.1186/1471-2407-14-397 Search in Google Scholar